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Abstract
The objective of this population-based study is to describe epidemiological and 
genetic features of breast and ovarian cancer in North Sardinia, Italy. Patients who 
carry a high-risk mutation in one or both of the BRCA genes (BRCA1 or BRCA2) 
have a significantly increased risk of developing breast/ovarian cancer (BOC) and 
other cancers (e.g., prostate cancer in male). Epidemiological data on incidence dis-
tribution of breast/ovarian cancer from 2016 to 2019 in North Sardinia are obtained 
from the local tumor registry and from the cumulative results of 209 genetic testing 
for BRCA gene mutations performed in all young breast cancer patients and all 
women (over 50 years) with family history of BOC (total of 164 cases); further, 45 
genetic testing is performed, on ovarian cancer patients, at any age. The results pro-
vide a different distribution of fraction mutations carried by women and a higher 
prevalence of the BRCA2 mutation in the north of Sardinia than the entire popula-
tion and highlight the presence of specific germline mutation associated with the 
“founder effect” in distinct genetic subgroups reflecting genetic drift. Advances 
in next-generation sequencing technology, data analysis, and clinical investigation 
have revolutionized efforts to identify potential targets for BRCA molecular-based 
therapeutic agents.
Keywords: BRCA1, BRCA2, genetic epidemiology, genetic testing, founder 
mutations, breast cancer (BC), ovarian cancer (OC), breast and ovarian cancer 
syndrome (BOC)
1. Introduction
Breast cancer (BC) is the second most common cancer in the female world 
population, with more than 1.3 million new cases every year [1]. Systemic treat-
ment of breast cancer is based on accurate knowledge of the clinical and molecular 
characteristics of the tumor and includes cytotoxic, hormonal, or biological agents. 
Therapies are used in the adjuvant, neo-adjuvant, and metastatic settings of BC 
patients. In general, systemic agents are active at the beginning of therapy in 90% 
of primary breast cancers and 50% of metastases. However, disease progression and 
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resistance to therapy are expected to occur in a variable period of time, though they 
are becoming a less common event.
Ovarian cancer (OC) is the seventh most common cancer in women from 
Western countries (about 5% of all cancers) [2]; its frequency however var-
ies widely among different geographic regions and ethnic groups, with a high 
incidence in Northern Europe and the United States and low rates in Africa and 
Asia. In Europe, about 61,000 new cases are estimated to be diagnosed per year. 
The age-adjusted world incidence is around 11 new cases per 100,000 inhabitants 
per year.
The majority of OC cases are sporadic, and only 5–10% of them are familial. 
Ovarian cancer is usually diagnosed at an advanced stage and etiology remains 
poorly understood. Nevertheless, about 30% of patients present with early-
stage disease (FIGO stage I–IIA). Surgery plays a main role in the treatment of 
epithelial ovarian cancer, and an extensive surgical staging is crucial in selecting 
the most appropriate systemic therapy. Several factors are associated with the 
onset of the epithelial ovarian cancer, including age (it is a disease of older age), 
genetic features (approximately, 5–10% of them result from a hereditary pre-
disposition), site-specific ovarian cancer syndrome (10–15% of all cases), and a 
positive family history with an affected first-degree relative (mother, daughter, 
or sister).
In the presence of the breast-ovarian cancer syndrome (BOC), families present 
with multiple cases (two or more) affected by ovarian and breast cancer in succes-
sive generations, tumors with earlier age of onset (usually in the premenopausal 
age), and evidence of both maternal and paternal transmission [3]. This hereditary 
syndrome has been linked to the BRCA1 gene at chromosome 17q12–21 (81% of 
cases) and, less frequently, to the BRCA2 gene at chromosome 13q.
Cumulative breast cancer risks by age 70 are estimated to be 65% for BRCA1 and 
45% for BRCA2 mutation carriers. In addition, women with BRCA mutations are at 
significant risk of developing ovarian cancer and other malignancies [4].
Both BRCA1 and BRCA2 encode proteins that are involved in maintenance 
of genome stability and in the repair of double-stranded DNA breaks (DSBs) by 
homologous recombination (HR).
HR is a potentially error-free mechanism of DNA damage repair that requires 
RAD51 localization to DSBs. BRCA2 interacts directly with RAD51 and is required 
for the formation of RAD51 complex, as is a BRCA2-associated protein called DSS1. 
The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, 
and these motifs mediate binding to the RAD51 recombinase, which functions in 
DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 
mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. 
BRCA1 is also required for the formation of RAD51 foci, perhaps through direct 
or indirect interaction with RAD51 or BRCA2 [5]. BRCA2 has also been identified 
as the FANCD1 gene, a member of the Fanconi anemia complex of proteins, and 
cells deficient in this protein have a similar phenotype to those deficient in BRCA 
[6]. Chromosomal instability as a result of BRCA1 or BRCA2 deficiency may be the 
pathogenic basis for breast tumor formation. In women who inherit an inactivating 
mutation, BRCA deficiency is critical to the development of disease and is the result 
of both the inherited inactivating allele and somatic genomic loss of the wild-type 
allele in breast or ovarian epithelial cells. The risk of developing BRCA-associated 
ovarian cancer is modified by several factors such as the reproductive history and 
hormonal exposure of an affected individual, and the coinheritance of modifying 
genes [6].
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2. Breast ovarian cancer family selection
The overall criteria to reconstruct the possible family history of patients with 
breast cancer can be established by identifying three risk levels: profile 1, level of 
cancer risk equivalent to general population; profile 2, level of cancer risk two-fold 
higher than that of general population; and profile 3, level of cancer risk three or 
more times higher than that of general population.
Six main criteria are taken into consideration to address women diagnosed with 
breast cancer into the general population to BRCA mutation testing: (a) younger 
women with breast cancer diagnosed at age less than 36 years; (b) affected male indi-
viduals (at any age of onset); (c) women with occurrence of both breast and ovarian 
cancer (at any age); (d) women with bilateral carcinoma diagnosed before 50 years; 
(e) women with triple-negative breast cancer who are younger than 50 years; and 
(f) all women with ovarian (and fallopian tube) carcinoma before 50 years or with 
high-grade serous ovarian cancer at any age.
Current guidelines recommend genetic testing for women diagnosed with breast 
cancer and at least one affected family member; a personal history of breast cancer 
and one or more relatives with breast cancer diagnosed before age 50; two or more 
relatives diagnosed with breast cancer at any age; one or more relatives with ovarian 
cancer; one or more relatives with male breast cancer, or two or more relatives with 
prostate cancer or pancreatic cancer.
In this sense, the American Society of Clinical Oncology, the American College 
of Obstetrics and Gynecology, and the National Comprehensive Cancer Network 
do not recommend BRCA mutation testing for women younger than 50 years 
with breast cancer unless there is a family history of breast/ovarian cancer [7, 8]. 
Therefore, many young women with breast cancer and lack of a family history 
of disease will not have the opportunity to undergo BRCA mutation testing. As a 
result of this, a significant proportion of newly diagnosed women with breast can-
cer who are younger than 50 years may not be identified as BRCA mutation carri-
ers, and they remain at high risk for subsequent breast and ovarian cancer. Positive 
BRCA mutation testing in women with ovarian carcinoma allows relatives access 
to oncological genetic counseling and preventive testing, aimed at verifying the 
presence or absence in family members, of pathogenic sequence variants. Genetic 
results are essential to carry out specific recommendations for clinical management 
of at-risk relatives. In the case of a positive result, the programs are aimed at pro-
moting screening strategies for early diagnosis as well as favoring primary preven-
tion interventions for the reduction in the risk of breast/ovarian cancer. The BRCA 
test is recommended for all patients with nonmucinous and nonborderline ovarian 
cancer, carcinoma of the fallopian tubes, or peritoneal primitive carcinoma. It is 
important to offer the BRCA test since cancer diagnosis. The identification of a 
pathogenic variant in BRCA genes also allows patients to plan an adequate thera-
peutic pathway. The identification of pathogenic variant in BRCA genes at germinal 
level in a patient with ovarian cancer allows to undertake a path of oncogenetic 
counseling in family members in order to identify high-risk carriers and to propose 
targeted programs for early diagnosis of syndrome-associated tumors with BRCA-
related and to carry out strategies aimed at reducing the risk.
In BRCA-mutated women, with ascertained diagnosis of ovarian cancer, a 
psychosocial approach must be envisaged, which takes into account the impact of 
the diagnosis and treatment on the physical and psycho-emotional sphere, as well 
as the psychological implications of the hereditary problem and the involvement of 
healthy family members at risk in the decision-making process [9].
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2.1 BRCA molecular profiling and epidemiology in Sardinia population
In Sardinia, breast cancer represents the principal death-causing malignancy, 
with an incidence similar to that observed in western countries [10]. Familial 
aggregation is thought to account for 5–10% of all breast cancer cases, and germline 
mutations in different genes involved in pathways critical to maintain the genomic 
integrity have accounted for less than 25% of the inherited breast cancer. Prevalence 
of mutation carriers with breast or ovarian cancer depends on the population 
studied and displays considerable variation based on ethnic and geographical 
diversity [11]. In Italy, 4–27% of the identified mutations recurred among appar-
ently unrelated families, while a regional founder effect has been demonstrated for 
few mutations; contribution of BRCA1–2 mutations to breast cancer predisposition 
has been reported for populations from the Northern part of Sardinia as well as 
strong founder effects for several genetic diseases were founded with some geo-
graphical differences within the island [12]. BRCA2 mutations are notably more 
recurrent than BRCA1 mutations in breast cancer families from North Sardinia [13]. 
Moreover, allelic transmission is identical in males and females as the entire popula-
tion should comply with the Hardy–Weinberg law [14].
In southern Italy, including Sardinia, standardized mortality rate in ovarian 
cancer patients is 8.5/100,000 lower than in Italy; also, the cumulative risk of death 
from the disease is extremely low (0.4%) [4, 15].
Germline mutations in either BRCA1 or BRCA2 genes occur in approximately 
10% of unselected women with ovarian cancer, and women with inherited BRCA1/2 
mutations are at significant risk of developing ovarian cancer [16].
The lifetime risk of developing ovarian cancer in women who carry a germline 
BRCA mutation has been estimated to be of 40–60% for BRCA1 and 11–27% for 
BRCA2 [17]. A meta-analysis of 22 studies with over 8000 disease probands has 
defined the incidence for ovarian cancer to be approximately 39% for BRCA1 and 
11% for BRCA2 [18]. In North Sardinia, less than 10% of breast cancer families 
presented an association with ovarian cancer (at least one affected family member) 
[12]. Nevertheless, the presence of ovarian cancer was demonstrated to significantly 
increase the occurrence of BRCA1/2 germline mutations in Sardinian breast cancer 
families [12, 19].
2.2  Next-generation sequencing approaches for mutation analyses  
in Sardinian population
In recent past years, epidemiological data have become available from the 
Cancer Registry of the Province of Sassari. This registry was created in 1992 by the 
Local Health Agency (Azienda Sanitaria Locale, ASL) of Sassari for the epidemio-
logical surveillance of tumors in the province. In 1999, it became part of wider web 
tumor registries, coordinated today by the Italian Association for Tumor Registries 
(Associazione Italiana Registri Tumori) [20]. Crude incidence and mortality rates 
for 100,000 inhabitants per year were calculated and standardized rates adjusted 
for European age population standards. The age-class distribution of cases was 
analyzed; relative incidence and mortality date was compared between Sardinia and 
the rest of Italy (Table 1).
Numerous studies by our group have assessed the BRCA1/2 mutation prevalence in 
various cohorts, although few have evaluated the predictors for the occurrence of both 
BRCA1 and BRCA2 mutations among younger patients in a hospital-based population.
Breast/ovarian cancer patients, originating from North Sardinia, were recruited 
from clinics at the University of Sassari and Local Health Agencies accounting for 
cancer patients from the Central and Northern part of the island (Sassari, Olbia, 
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Nuoro). Sardinian origin was ascertained in all cases through genealogical studies. 
Patients with a histologically-proven diagnosis of breast/ovarian cancer diagnosed 
before 50 years were consecutively-collected during a period of 4 years; no addi-
tional selection criteria were used for their inclusion into the study.
In such a population-based series of early-onset breast/ovarian cancer, family 
history of breast and ovarian cancers were assessed according to the above-described 
standardized criteria. Patients were informed of the aims of the study and blood 
samples were obtained with their written consent. Genomic DNA was isolated and 
next-generation sequencing (NGS) investigations were performed using a specific 
BRCA1/2 gene. Research assay panel allows to detect simultaneously point mutations 
and CNVs. Samples were sequenced on the Ion Torrent S5 System (Life Technologies, 
Waltham, MA, USA), and data were processed with the Ion Torrent platform.
Between 2016 and 2019, 209 patients originating from North Sardinia under-
went the NGS-based mutation analyzed in BRCA1/2 genes; among them, 164 were 
diagnosed with primary breast cancer and 45 with primary ovarian cancer, with 
median age at onset of 51 years (range 27 ± 84), any age for ovarian cancer.
Patients with first diagnosis of breast cancer were evaluated for familial occur-
rence of malignancy using a questionnaire to interview probands about their first- 
and second-degree relatives. In our series of Sardinian cases, we analyzed sporadic 
young patients with a breast cancer diagnosis before 50 years (59/164; 36%) and 
any familiar history; a number of probands with a positive family history for breast 
cancer (33/164; 20%) and age of onset before 50 years; and patients (72/164; 44%) 
with breast/ovarian cancer familiar history at any age. Moreover, the analysis was 
performed on 45 (45/209; 21.5%) ovarian cases at any age.
2.3 Deleterious variants in BRCA1 and BRCA2 genes
Overall, prevalence of deleterious BRCA1/2 variants was 10 times higher in 
patients with a positive family history (19/105; 18.09%) as compared with those 
with sporadic tumors (2/104; 1.92%). Interestingly, all uncertain variants-that is, 
those with unknown functional significance-were nearly completely prevalent in 
Age class No. of 
cases
% of cases
A: age-class incidence distribution of breast cancer cases (N = 164) in North Sardinia, 2016–2019
0–14 — —
15–29 2 1.2
30–40 37 22.5
40–50 53 32.3
*50+ 72 43.9
B: age-class incidence distribution of ovarian cancer cases (N = 45) in North Sardinia, 2016–2019
0–14 — —
15–29 — —
30–44 4 8.9
45–59 17 37.8
60–74 18 40
75+ 6 13.3
*Asterisk indicates familial breast cancer patients.
Table 1. 
Epidemiological data in North Sardinia.
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familiar tumor cases. Deleterious variants were found in 68% (15/22) of breast 
cancer cases and 31.8% (7/22) of ovarian cancer cases; variants with unknown 
significance (VUS) were observed in 81.2% of breast cancer patients and in 18.7% 
of ovarian cancer patients. Deleterious germline variants in BRCA2 5.74% (12/209) 
were featured, followed by BRCA1 4.78%(10/209) patients according to our previ-
ous study that explained a different geographical distribution of BRCA1–2 muta-
tions with a higher prevalence of the BRCA2 mutation in the north of Sardinia than 
the entire population [19].
Among families with high recurrence of breast cancer (≥ 3 cases in first-degree 
relatives), almost all ones from northern Sardinia were previously demonstrated by 
our group to share the same haplotype and carry a single mutation in BRCA2 gene 
(BRCA2-8765delAG), which thus acts as a pathogenic variant with founder effect in 
the population of this part of the island (due to the occurrence and propagation of 
a common ancestral deleterious alteration) [21]. The BRCA2-8765delAG mutation 
was firstly described in breast cancer families from French-Canadian and Jewish-
Yemenite populations; however, the families from French Canadian and Jewish-
Yemenite populations were demonstrated to present with distinct genetic assets at 
the BRCA2 locus, arguing thus against a common origin of this mutation among 
such different populations (it seems to be conducted to the high propensity to dele-
tion error in this part of the BRCA2 gene, within a so-called hot-spot mutational 
region) [22] (Table 2).
Few BRCA functional mutations account for BRCA-associated cancers among 
homogenous populations such as Sardinia (a single BRCA2 founder mutation), 
French-Canadian population (French colonization of the province of Quebec, 
five recurrent mutations of which one is common with Sardinia BOC family), and 
Jewish-Yemenite Ashkenazi Jewish families of eastern European ancestry (specific 
subpopulations; three recurrent founder mutations are known), while more hetero-
geneous populations tend to display a broad mutation spectrum; founder mutations 
are specific mutations that appear repeatedly in ethnically defined groups because 
of a shared common ancestry [23].
The presence of a singleBRCA2 mutation that is extremely rare (in less than 
1% of breast cancer cases) is characterized in another isolated population such as 
Iceland, which explains a substantial proportion of the familial risk of breast cancer 
in Iceland and accounts for most of the prostate and ovarian cancer observed in 
families of breast cancer patients [24].
The epidemiological and clinical impact of the BRCA2 founder mutation on 
cancer in isolated population has been extensively studied, particularly with regard 
to significantly higher risk of BOC. The mutations fall into cluster region of BRCA-
gene and can be associated with significantly higher risk of breast and ovarian 
cancer in female population and prostate cancer in males.
Women carrying ascertained pathogenic mutations have a higher lifetime risk 
of the disease. It’s estimated that 55–65% of women with a germinal mutation 
in BRCA1 will develop breast cancer before age 70. In our series, median age of 
first diagnosis of breast cancer was 42.5 years (range 27 ± 50); the median value 
increases significantly up to 57 years (range 39 ± 83) in ovarian cancer cases. 
Approximately 45% of women with a BRCA2 mutation will develop breast cancer 
by age 70.
BRCA2 mutation carrier patients with a family history of breast cancer have 
early median onset of 44 years (range 27 ± 54). The increase of median value is 
even more significant in ovarian cancer patients selected at any age: 59 years (range 
48 ± 77).
Cancers related to a BRCA1 mutation are also more likely to be triple-negative 
breast cancer, which can be more aggressive and difficult to treat. Triple-negative 
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Gene Transcript Coding Protein Function dbSNP Clinical Significance Enigma
BRCA1 NM_007294.3 c.1519 A > T p.Arg507 Ter Non sense rs397508880 Pathogenic Yes
BRCA1 NM_007294.3 c.1513 A > T p.Lys505 Ter Non sense rs397508877 Pathogenic Yes
BRCA1 NM_007294.3 c.799 dupT p.Ser267 fs Frame shift deletion rs80357724 Pathogenic Yes
BRCA1 NM_007294.3 c.981_982 del p.Cys328 fs Frame shift deletion rs80357772 Pathogenic No*
BRCA1 NM_007294.3 c.1380 dupA p.F461Ifs Frame shift deletion rs80357714 Pathogenic Yes
BRCA1 NM_007294.3 c.1953 delG Lys654 Ser Frame shift deletion rs80357522 Pathogenic Yes
BRCA1 NM_007294.3 c.190 T > C p.Cys64 Arg Missense rs80357064 Pathogenic Yes
BRCA2 NM_000059.3 c.8533_8534 AG p.Glu2846fs Frame shift deletion rs80359714 Pathogenic Yes
BRCA2 NM_000059.3 c.7683_7684 del p.Gln2561fs Frame shift deletion rs766251541 Pathogenic Yes
BRCA2 NM_000059.3 c.815 A > T p.Asn272 Ile Missense rs1555067189 Pathogenic Yes
BRCA2 NM_000059.3 c.6037 A > T p.Lys2013 Ter Nonsense rs80358840 Pathogenic Yes
BRCA2 NM_000059.3 c.2808_2811delACAA p.Ala938fs Frame shift deletion rs80359351 Pathogenic Yes
*Indicates a variant classified as pathogenic by only ClinVar database and not provided by Enigma.
Table 2. 
Variants detected by NGS BRCA panel. Classification criteria were according to the enigma 2015 database.
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breast cancer has been classified as a breast cancer subgroup with lack of ER, PR, 
and HER2 expression and accounts for 15 to 20% of breast cancer cases. Despite a 
notably favorable rate of response to chemotherapy, triple-negative patients present 
with a higher risk of relapse and a relatively poor outcome [25].
3. BRCA-related treatments
For breast cancer, treatment options depend on the stage of disease and other 
factors such as tumor size, results of specific pathology tests (hormone receptors, 
HER2 receptors, grade of the cells, and proliferation rate of the cells), family his-
tory or other risk factors associated with a predisposition for developing breast or 
ovarian cancer, and age.
Most women with ductal carcinoma in situ (DCIS), a noninvasive breast cancer, 
have breast-conserving surgery, also known as lumpectomy followed by radiation 
therapy [26]. Chemotherapy before surgery in women with large stage II or IIIA 
breast tumors is neo-adjuvant therapy to make possible that breast-conserving 
surgery. Moreover, after surgery, adjuvant therapy and radiation treatment lower 
the chance of breast cancer returning [27].
The presence of positive hormone receptor tumor cells is called estrogen recep-
tor-positive (ER-positive) breast cancer; standard hormone therapy (tamoxifen) is 
based on drug administration that blocks the action of estrogen or prevents it from 
binding to the estrogen receptor [28]. Among women whose tumors do not express 
the estrogen receptor (ER-negative breast cancer) and are positive for progesterone 
receptor (PR), tamoxifen has no effect on recurrence [29].
Herceptin (trastuzumab) can be used to treat HER2-positive breast cancer that 
is either early-stage or advanced stage/metastatic [30]; it is a humanized mono-
clonal antibody, specifically used in breast carcinomas in which the HER2/neu 
transmembrane protein is overexpressed [31]. Herceptin is currently approved to 
treat metastatic HER2-positive breast cancer to stop the cancer from growing; to 
treat earlier stages of HER2-positive breast cancer, either as part of a regimen with 
chemotherapy or alone after a chemotherapy regimen that includes an anthracy-
cline; and to reduce the risk of the breast cancer coming back (recurrence) [32], 
in combination with pertuzumab and docetaxel before surgery to treat HER2-
positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the 
lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high 
risk of metastasizing or becoming fatal [33]. Moreover, adjuvant treatment (after 
surgery) with the combination of pertuzumab, trastuzumab, and chemotherapy 
significantly reduces the risk of recurrence of breast cancer or death in women with 
early-stage cancer HER2-positive compared to the therapeutic standard consisting 
of trastuzumab and chemotherapy [34].
Patients with advanced diagnosis of ovarian cancer are expected to relapse 
within 3 years, after standard treatment with surgery and chemotherapy (carbopla-
tin-Taxol) [35]. Platinum-based therapy continues to be the principal regimen used 
to treat ovarian tumors that recur at least 6 months after prior therapy [36].
Carboplatin monotherapy is very convenient to administer, is well tolerated, and 
produces relatively high response rates (RRs). However, the response usually lasts for 
only a few months, and with each subsequent course of therapy, the treatment-free 
interval usually becomes shorter until the tumor is declared ‘platinum resistant.’ 
Several studies have combined platinum-based drugs with other agents. Combinations 
increase the tumor RR and extend the progression-free survival (PFS) [37, 38].
Targeted therapy of ‘platinum-sensitive’ recurrent OC is conducted in patients 
at different stages of the treatment pathway. Two classes of drug are being 
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extensively explored in the ‘platinum-sensitive’ group. These are inhibitors of 
angiogenesis, an important driver of tumor growth, with a humanized monoclonal 
antibody, bevacizumab, directed against circulating vascular endothelial growth 
factor (VEGF) A, an important ligand that binds to the VEGF receptor (VEGFR), 
stimulating angiogenesis and poly-ADP ribose polymerase (PARP) inhibitors that 
are active in patients with BRCA gene mutations, and those deficient in the repair of 
DNA damage through homologous recombination [39, 40].
A germline mutation in one BRCA1 or BRCA2 (gBRCAm) allele is associated 
with a high risk of the development of a number of cancers, including breast, ovar-
ian, and prostate cancer [41, 42]. Heterozygous BRCA mutations determine loss 
of function of the remaining wild-type allele, resulting in deficient homologous-
recombination DNA repair, which causes genetic aberrations that drive carcinogen-
esis; the inactivation of the wild-type allele in the tumor is thought to be an obligate 
step in this process [43, 44].
This tumor-specific defect can be exploited by using PARP inhibitors (e.g., 
olaparib) to induce selective tumor cytotoxicity, sparing normal cells. Poly(ADP-
ribose) polymerase (PARP) is an enzyme involved in base excision repair mecha-
nisms, enabling the adjustment of DNA single-strand breaks repair [45]. Different 
Parp inhibitors were approved by US FDA: olaparib was approved for use in women 
with deleterious germline BRCA mutated advanced ovarian cancer and deleterious 
gBRCAm HER2-negative metastatic breast cancer, while rucaparib was approved 
for use in women with germline and/or somatic BRCA mutation in advanced ovar-
ian cancer. Several additional Parp inhibitors are in late-phase clinical trials [46].
PARP inhibition in mutated tumor cells with deficient homologous-recombina-
tion repair generates unrepaired DNA single-strand breaks that are likely to cause the 
accumulation of DNA double-strand breaks and collapsed replication forks [47, 48]. 
Contrariwise, the normal tissue cells that are heterozygous for BRCA mutations and 
that therefore retain homologous-recombination function have a sensitivity to PARP 
inhibitors similar to that of wild-type cells, predicting a high therapeutic effect for 
PARP inhibition in BRCA carriers [49, 50].
The benefits of olaparib (as inhibitor of poly-adenosine diphosphate ribose 
polymerase) are already widely known in disease relapses. The SOLO-1 study, a 
double-blind, randomized, prospective phase 3 trial, went to explore for the first 
time the effects of olaparib as a maintenance therapy, immediately after surgery 
and chemotherapy, in the newly diagnosed tumor forms, advanced (phase III-IV), 
BRCA mutated, with a partial or complete clinical response after chemotherapy. 
Results of the study are encouraging: after a median follow-up of 41 months, the 
risk of disease progression and/or mortality was 70% lower in patients treated with 
olaparib than in the control group [51].
4. Conclusions
Genetic testing for breast and ovarian cancer has clinical importance for identi-
fication of potentially affected families and for cancer prevention. Approximately, 
only 5–10% of breast and ovarian cancer are familiar.
Sardinia population shows genetic peculiarity due to geographical isolation and 
strong genetic drift. The geographical distribution of BRCA1–2 mutations is related 
to three specific large areas of Sardinia, reflecting its ancient history: the Northern 
area, linguistically different from the rest of the island where a BRCA2-8765delAG 
mutation with founder effect, already displayed in our previously study, is pre-
dominant [19]. Considering the incidence of the BRCA2-8765delAG variant among 
the unselected patients from the Sardinian population, our extensive past screening 
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clearly indicated that such a mutation is recurrent in North Sardinia, confirming its 
role as founder mutation in this part of the island but absent in South Sardinia [52].
Breast cancer families originating from South Sardinia, where BRCA1 mutations 
are demonstrated to be much more prevalent, present markedly higher rates of 
association with ovarian cancer [12].
BRCA2 mutations were notably more recurrent than BRCA1 mutations in breast 
cancer families from North Sardinia and less than 10% of breast cancer families 
presented an association with ovarian cancer (at least one affected family member) 
[17]. Nevertheless, the presence of ovarian cancer was demonstrated to significantly 
increase the occurrence of BRCA1/2 germline mutations in Sardinian breast cancer 
families [12, 19].
The incidence and mortality trends of ovarian cancer in North Sardinia 
remained relatively stable in the last decade with cumulative risk of death from 
the disease being low. Furthermore, survival of patients with ovarian cancer was 
relatively good in the area, sanctioning the adequacy of the preventive and clinical 
measures employed in the management of the disease. As for other malignancies, 
concurrence of different environmental factors and genetic backgrounds may 
determine the incidence of ovarian cancer.
4.1 Future perspectives
The identification of pathogenic mutations makes it possible to identify, within 
familial cases, a subpopulation of individuals who present mutations in BRCA-
genes. In this classification, however, individuals in whom deleterious mutations 
could not be identified are excluded, despite having an important family history. 
Furthermore, the uncertain variants of two major genes do not explain the cancer 
susceptibility to germ cells.
The future venue of this study is to extend the analysis to possible minor 
breast cancer susceptibility genes involved in homologous recombination 
pathways and in repair mechanisms, thanks to the use of increasingly advanced 
sequencing technologies that involve the use of multigene cancer panels. 
Functional study and bioinformatics prediction tools provide a putative clinical 
significance for the identification of somatic variants of interaction between 
BRCA1 and DNA repair genes and may contribute to identify a role many genes in 
cancer development.
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